
Predictive Oncology POAI
Annual report 2025
added 03-31-2026
Predictive Oncology Interest Expense 2011-2026 | POAI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Predictive Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 3 | 391 K | 378 K | 637 K | 259 K | 230 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 637 K | 3 | 316 K |
Quarterly Interest Expense Predictive Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.22 K | - | - | - | - | - | - | - | - | - | - | 3 | - | - | - | 51.8 K | 189 K | 154 K | - | 132 K | 14.8 K | 18.1 K | - | 408 K | 127 K | 95.6 K | - | 23.7 K | 89.3 K | 55.5 K | - | 61 K | 57.9 K | 57.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 408 K | -3.22 K | 90.1 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
-16.4 M | $ 60.79 | 0.68 % | $ 12.1 B | ||
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
iRhythm Technologies
IRTC
|
5.44 M | $ 115.17 | 0.88 % | $ 3.69 B | ||
|
ICU Medical
ICUI
|
93.3 M | $ 121.75 | -1.01 % | $ 3 B | ||
|
Repro Med Systems
KRMD
|
9.91 K | $ 3.89 | -2.26 % | $ 180 M | ||
|
LeMaitre Vascular
LMAT
|
5.18 M | $ 99.14 | -0.36 % | $ 2.24 B | ||
|
Alcon
ALC
|
204 M | $ 64.53 | 0.8 % | $ 40.4 B | ||
|
Masimo Corporation
MASI
|
300 K | $ 178.4 | 0.03 % | $ 9.51 B | ||
|
Ekso Bionics Holdings
EKSO
|
-26 K | - | - | $ 28.6 M | ||
|
Envista Holdings Corporation
NVST
|
-2.3 M | $ 23.88 | 0.13 % | $ 4.01 B | ||
|
electroCore
ECOR
|
14.9 K | $ 6.3 | -2.02 % | $ 53.4 K | ||
|
Haemonetics Corporation
HAE
|
-9.75 M | $ 56.86 | -0.4 % | $ 2.86 B | ||
|
STAAR Surgical Company
STAA
|
2.25 M | $ 31.88 | -0.42 % | $ 1.58 B | ||
|
STERIS plc
STE
|
8.4 M | $ 215.75 | -0.17 % | $ 21.3 B | ||
|
Teleflex Incorporated
TFX
|
85.1 M | $ 130.11 | -0.13 % | $ 5.81 B | ||
|
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
13.6 M | $ 142.59 | 0.3 % | $ 6.91 B | ||
|
InfuSystem Holdings
INFU
|
2 K | $ 8.53 | -1.24 % | $ 176 M | ||
|
Microbot Medical
MBOT
|
-5 K | $ 1.92 | 3.51 % | $ 87.9 M | ||
|
Milestone Scientific
MLSS
|
60.3 K | $ 0.34 | -0.15 % | $ 27.9 M | ||
|
Merit Medical Systems
MMSI
|
-2.39 M | $ 62.51 | -0.08 % | $ 3.7 B | ||
|
Utah Medical Products
UTMD
|
-120 K | $ 63.24 | -0.72 % | $ 205 M | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 302.94 | 0.92 % | $ 21.9 B | ||
|
Pulse Biosciences
PLSE
|
-52 K | $ 24.97 | -7.88 % | $ 1.68 B | ||
|
DENTSPLY SIRONA
XRAY
|
24 M | $ 10.04 | -3.6 % | $ 2 B | ||
|
Retractable Technologies
RVP
|
227 K | $ 0.69 | - | $ 20.7 M | ||
|
Pro-Dex
PDEX
|
533 K | $ 59.29 | 1.09 % | $ 195 M | ||
|
BioLife Solutions
BLFS
|
1.82 M | $ 20.77 | -1.36 % | $ 992 M | ||
|
Stereotaxis
STXS
|
2 K | $ 1.88 | -3.34 % | $ 171 M | ||
|
Baxter International
BAX
|
290 M | $ 17.56 | -1.29 % | $ 9.01 B | ||
|
ResMed
RMD
|
3.2 M | $ 204.64 | 1.03 % | $ 29.9 B | ||
|
AtriCure
ATRC
|
683 K | $ 28.64 | 1.72 % | $ 1.37 B | ||
|
Harvard Bioscience
HBIO
|
-2.66 M | $ 5.48 | -0.69 % | $ 243 M | ||
|
AngioDynamics
ANGO
|
4.94 M | $ 11.01 | -0.18 % | $ 450 M | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 143.69 | -0.57 % | $ 41.3 B | ||
|
Nephros
NEPH
|
-78 K | $ 3.21 | -3.94 % | $ 34.1 M | ||
|
OraSure Technologies
OSUR
|
229 K | $ 3.04 | 3.05 % | $ 223 M | ||
|
Repligen Corporation
RGEN
|
2.82 M | $ 105.54 | 2.09 % | $ 5.93 M |